Tailored-pharmacophore model to enhance virtual screening and drug discovery: a case study on the identification of potential inhibitors against drug-resistant Mycobacterium tuberculosis (3R)-hydroxyacyl-ACP dehydratases

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Lawn SD, Zumla AI. Tuberculosis. Lancet 378(9785), 57–72 (2011).
  MedlineGoogle Scholar
• 2 Ntoumi F, Kaleebu P, Macete E et al. Taking forward the World TB Day 2016 theme “Unite to End Tuberculosis” for the WHO Africa Region. Int. J. Infect. Dis. 46, 34–37 (2016).
  MedlineGoogle Scholar
• 3 WHO. Global Tuberculois Report 2015 – Executive Summary (2015). www.who.int/tb/publications/global_report/gtbr2015_executive_summary.pdf.
  Google Scholar
• 4 Who. Global Tuberculosis Report 2016. www.who.int/tb/publications/global_report/en/.
  Google Scholar
• 5 Wood R, Lawn SD, Johnstone-Robertson S, Bekker LG. Tuberculosis control has failed in South Africa – time to reappraise strategy. South African Med. J. 101(2), 111–114 (2016).
  Google Scholar
• 6 Bocchino M, Matarese A, Sanduzzi A. Current treatment options for latent tuberculosis infection. J. Rheumatol. Suppl. 91, 71–77 (2014).
  Medline CASGoogle Scholar
• 7 Kling A, Lukat P, Almeida DV et al. Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins. Science 348(6239), 1106–1112 (2015).
  Medline CASGoogle Scholar
• 8 Machaba KE, Cele FN, Mhlongo NN, Soliman MES. Sliding clamp of DNA polymerase III as a drug target for TB therapy: comprehensive conformational and binding analysis from molecular dynamic simulations. Cell Biochem. Biophys. 74(4), 473–481 (2016).
  Medline CASGoogle Scholar
• 9 Dong Y, Qiu X, Shaw N et al. Molecular basis for the inhibition of hydroxyacyl-ACP dehydratase HadAB complex from Mycobacterium tuberculosis by flavonoid inhibitors. Protein Cell 6(7), 504–517 (2015). •• Presents an investigation of MtbHadAB and provides the first 3D atomic models of the MtbHadAB-inhibitor complexes. The 3D crystal structure of MtbHadAB hetero-dimer from this article was used as an initial structure in our work.
  Medline CASGoogle Scholar
• 10 Bhatt A, Molle V, Besra GS, Jacobs WR, Kremer L. The Mycobacterium tuberculosis FAS-II condensing enzymes: their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development. Mol. Microbiol. 64(6), 1442–1454 (2007).
  Medline CASGoogle Scholar
• 11 Takayama K, Wang C, Besra GS. Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis genetic analysis of synthesis and processing of mycolic acid. Society 18(1), 81–101 (2005).
  CASGoogle Scholar
• 12 Dong Y, Li J, Qiu X, Yan C, Li X. Expression, purification and crystallization of the (3R)-hydroxyacyl-ACP dehydratase HadAB complex from Mycobacterium tuberculosis. Protein Expr. Purif. 114, 115–120 (2015).
  Medline CASGoogle Scholar
• 13 Cantaloube S, Veyron-Churlet R, Haddache N, Daffé M, Zerbib D. The Mycobacterium tuberculosis FAS-II dehydratases and methyltransferases define the specificity of the mycolic acid elongation complexes. PLoS ONE 6(12), e29564 (2011).
  Medline CASGoogle Scholar
• 14 Grzegorzewicz AE, Eynard N, Quémard A et al. Covalent modification of the Mycobacterium tuberculosis FAS-II dehydratase by isoxyl and thiacetazone. ACS Infect Dis. 1(2), 91–97 (2016). • Unveils for the first time the nature of the active forms of thiacetazone (TAC) and explains the basis for the structure–activity relationship of and resistance to these prodrug. This article is useful because the information is up-to-date and from a reliable source
  Google Scholar
• 15 Campbell JW, Cronan Jr. JE. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. 55, 305–332 (2001). • This article encompasses the known inhibitors and prospective targets for new antibacterial. The work provide a strong theoretical background related to our work.
  Medline CASGoogle Scholar
• 16 Marrakchi H, Lanéelle MA, Daffé M. Mycolic acids: structures, biosynthesis, and beyond. Chem. Biol. 21(1), 67–85 (2014).
  Medline CASGoogle Scholar
• 17 Alahari A, Trivelli X, Guérardel Y et al. Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS ONE 2(12), e1343 (2007).
  MedlineGoogle Scholar
• 18 Grzegorzewicz AE, Kordulakova J, Jones V et al. A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. J. Biol. Chem. 287(46), 38434–38441 (2012).
  Medline CASGoogle Scholar
• 19 Belardinelli JM, Morbidoni HR. Mutations in the essential FAS II β-hydroxyacyl ACP dehydratase complex confer resistance to thiacetazone in Mycobacterium tuberculosis and Mycobacterium kansasii. Mol. Microbiol. 86(3), 568–579 (2012). • Provides structural study of MtbHadAB and unveils the MtbHadAB binding mechanism as well as thiacetazone resistance. The authors provide a strong theoretical background.
  Medline CASGoogle Scholar
• 20 Fernández-Bachiller MI, Horatscheck A, Lisurek M, Rademann J. Alzheimer's disease: identification and development of β-secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS). ChemMedChem 8(7), 1041–1056 (2013).
  Medline CASGoogle Scholar
• 21 Kumalo HM, Soliman ME. Per-residue energy footprints-based pharmacophore modeling as an enhanced in silico approach in drug discovery: a case study on the identification of novel β-secretase1 (BACE1) inhibitors as anti-alzheimer agents. Cell Mol. Bioeng. 9(1), 175–189 (2016). •• Presents a novel virtual screening approach (Per-Residue Energy Footprints-Based Pharmacophore Modeling), which was a further improvement of a previously published ‘target-bound pharmacophore modeling approach’. The main goal of the present work is not to validate the approach, but rather improve and refine the approach to identify potential inhibitors against resistance mutations.
  CASGoogle Scholar
• 22 Hossain T, Mukherjee A, Saha A. Chemometric design to explore pharmacophore features of BACE inhibitors for controlling Alzheimer's disease. Mol. Biosyst. 11(2), 549–557 (2015).
  Medline CASGoogle Scholar
• 23 Huang D, Liu Y, Shi B, Li Y, Wang G, Liang G. Comprehensive 3D-QSAR and binding mode of BACE-1 inhibitors using R-group search and molecular docking. J. Mol. Graph. Model. 45, 65–83 (2013).
  Medline CASGoogle Scholar
• 24 Halperin I, Ma B, Wolfson H, Nussinov R. Principles of docking: an overviewof search algorithms and a guide to scoring functions. Proteins Struct. Funct. Genet. 47, 409–443 (2002).
  Medline CASGoogle Scholar
• 25 Kitchen D, Decornez H, Furr J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug 3(11), 935–949 (2004).
  Medline CASGoogle Scholar
• 26 Appiah-Kubi P, Soliman M. Hybrid receptor-bound/MM-GBSA-per-residue energy-based pharmacophore modelling: enhanced approach for identification of selective LTA4H inhibitors as potential anti-inflammatory drugs. Cell Biochem. Biophys. 75(1), 35–48 (2016).
  MedlineGoogle Scholar
• 27 Soliman MES. A hybrid structure/pharmacophore-based virtual screening approach to design potential leads: a computer-aided design of South African HIV-1 subtype C protease inhibitors. Drug Dev. Res. 74(5), 283–295 (2013).
  CASGoogle Scholar
• 28 Cele FN, Ramesh M, Soliman MES. Per-residue energy decomposition pharmacophore model to enhance virtual screening in drug discovery: a study for identification of reverse transcriptase inhibitors as potential anti-HIV agents. Drug Des. Dev. Ther. 10, 1365–1377 (2016).
  Medline CASGoogle Scholar
• 29 Skelton AA, Maharaj YR, Soliman MES. Target-bound generated pharmacophore model to improve the pharmacophore-based virtual screening: identification of G-protein human CCR2 receptors inhibitors as anti-inflammatory drugs. Cell Mol. Bioeng. 7(1), 45–57 (2014).
  CASGoogle Scholar
• 30 Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J. Chem. Inf. Model. 52(7), 1757–1768 (2012).
  Medline CASGoogle Scholar
• 31 Trott O, Olson AJ. AutoDock Vina. J. Comput. Chem. 31, 445–461 (2010).
  Google Scholar
• 32 Sandeep G, Nagasree KP, Hanisha M, Kumar MMK. AUDocker LE: A GUI for virtual screening with AUTODOCK Vina. BMC Res. Notes 4(1), 445 (2011).
  MedlineGoogle Scholar
• 33 Morris GM, Goodsell DS, Halliday RS et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19(14), 1639–1662 (1998).
  CASGoogle Scholar
• 34 Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera – a visualization system for exploratory research and analysis. J. Comput. Chem. 25(13), 1605–1612 (2004).
  Medline CASGoogle Scholar
• 35 Case DA, Cheatham TE, Darden T et al. The Amber biomolecular simulation programs. J. Comput. Chem. 26(16), 1668–1688 (2005). •• Amber is one of the programs that allows users to carry out and analyze molecular dynamics simulations. Hence, Amber was utilized to study ligand binding in the current study.
  Medline CASGoogle Scholar
• 36 Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79(2), 926 (1983).
  CASGoogle Scholar
• 37 Harvey MJ, De Fabritiis G. An implementation of the smooth particle mesh Ewald method on GPU hardware. J. Chem. Theory Comput. 5(9), 2371–2377 (2009).
  Medline CASGoogle Scholar
• 38 Chetty S, Soliman MES. Possible allosteric binding site on Gyrase B, a key target for novel anti-TB drugs: homology modelling and binding site identification using molecular dynamics simulation and binding free energy calculations. Med. Chem. Res. 24(5), 2055–2074 (2015).
  CASGoogle Scholar
• 39 Bhakat S, Martin AJM, Soliman MES. An integrated molecular dynamics, principal component analysis and residue interaction network approach reveals the impact of M184V mutation on HIV reverse transcriptase resistance to lamivudine. Mol. Biosyst. 10(8), 2215–2228 (2014).
  Medline CASGoogle Scholar
• 40 Zhou Z, Madura JD. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS. Proteins Struct. Funct. Genet. 57(3), 493–503 (2004).
  Medline CASGoogle Scholar
• 41 Zhigang Z, Yanli W, Bryant SH. Computational analysis of the cathepsin B inhibitors activities through LR-MMPBSA binding affinity calculation based on docked complex. J. Comput. Chem. 30(14), 2165–2175 (2009).
  MedlineGoogle Scholar
• 42 Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov. 10(5), 449–461 (2015). • Presents molecular mechanics/Poisson–Boltzmann surface area and molecular mechanics/Generalized-Boltzmann surface area methods that are popular approaches to estimate the free energy of the binding of small ligands to biological macromolecules. Therefore, the article is useful for an analysis of the free energy of the binding of thiacetazone to MtbHadAB.
  Medline CASGoogle Scholar
• 43 Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model. 45(1), 160–169 (2005). •• Presents the algorithms for ligand extraction and interpretation as well as the pharmacophore creation technique. Hence, this article assists with pharmacophore creation technique and screening.
  Medline CASGoogle Scholar
• 44 Fuglebakk E, Echave J, Reuter N. Measuring and comparing structural fluctuation patterns in large protein datasets. Bioinformatics 28(19), 2431–2440 (2012).
  Medline CASGoogle Scholar